Overall tumor genomic instability: an important predictor of recurrence-free survival in patients with localized clear cell renal cell carcinoma

References

• The Cancer Genome Atlas Research Network, Creighton CJ, Morgan M, Gunaratne PH. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–49.
   PubMedGoogle Scholar
• Klatte T, Kroeger N, Rampersaud EN, Birkhäuser FD, Logan JE, Sonn G, Riss J, Rao PN, Kabbinavar FF, Belldegrun AS, et al. Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. Cancer. 2012;118:5777–5782. doi:10.1002/cncr.v118.23.
   PubMed Web of Science ®Google Scholar
• Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009;27:746–753. doi:10.1200/JCO.2007.15.8345.
   PubMed Web of Science ®Google Scholar
• La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, Shuch B, Zomorodian N, Kabbinavar F, Belldegrun A, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer. 2010;116:4696–4702. doi:10.1002/cncr.v116:20.
   PubMed Web of Science ®Google Scholar
• Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006;38:1043–1048. doi:10.1038/ng1861.
   PubMed Web of Science ®Google Scholar
• Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, et al. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife. 2018;7:e37294. doi:10.7554/eLife.37294.
   PubMed Web of Science ®Google Scholar
• Hieronymus H, Schultz N, Gopalan A, Carver BS, Chang MT, Xiao Y, Heguy A, Huberman K, Bernstein M, Assel M, et al. Copy number alteration burden predicts prostate cancer relapse. Proc Natl Acad Sci U S A. 2014;111:11139–11144. doi:10.1073/pnas.1411446111.
   PubMed Web of Science ®Google Scholar
• Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, et al. Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol. 2017;13:914. doi:10.15252/msb.20167159.
   PubMed Web of Science ®Google Scholar
• Ball MW, Gorin MA, Drake CG, Hammers HJ, Allaf ME. The landscape of whole-genome alterations and pathologic features in genitourinary malignancies: an analysis of the cancer genome atlas. Eur Urol Focus. 2017;3:584–589. doi:10.1016/j.euf.2017.01.007.
   PubMedGoogle Scholar
• Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O’Brien T, Lopez JI, Watkins TBK, Nicol D, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell. 2018;173:595–610.e11. doi:10.1016/j.cell.2018.03.043.
   PubMed Web of Science ®Google Scholar
• Endesfelder D, Burrell R, Kanu N, McGranahan N, Howell M, Parker PJ, Downward J, Swanton C, Kschischo M. Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. Cancer Res. 2014;74:4853–4863. doi:10.1158/0008-5472.CAN-13-2664.
   PubMed Web of Science ®Google Scholar
• Mitsumori K, Kittleson JM, Itoh N, Delahunt B, Heathcott RW, Stewart JH, McCredie MRE, Reeve AE. Chromosome 14q LOH in localized clear cell renal cell carcinoma. J Pathol. 2002;198:110–114. doi:10.1002/(ISSN)1096-9896.
   PubMed Web of Science ®Google Scholar
• Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13:7388–7393. doi:10.1158/1078-0432.CCR-07-0411.
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643–649. doi:10.1038/25292.
   PubMed Web of Science ®Google Scholar
• Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R, Cowley G, Lizotte P, Liberzon E, Bair S, et al. SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell. 2013;24:738–750. doi:10.1016/j.ccr.2013.10.025.
   PubMed Web of Science ®Google Scholar
• Kardas I, Mrozek K, Babinska M, Krajka K, Hadaczek P, Lubinski J, Roszkiewicz A, Kuziemska E, Limon J. Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas. Oncol Rep. 2005;13:949–956.
   PubMed Web of Science ®Google Scholar
• Ito T, Pei J, Dulaimi E, Menges C, Abbosh PH, Smaldone MC, Chen DYT, Greenberg RE, Kutikov A, Viterbo R, et al. Genomic copy number alterations in renal cell carcinoma with sarcomatoid features. J Urol. 2016;195:852–858. doi:10.1016/j.juro.2015.10.180.
   PubMed Web of Science ®Google Scholar
• El-Mokadem I, Fitzpatrick J, Bondad J, Rauchhaus P, Cunningham J, Pratt N, Fleming S, Nabi G. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery. BrJ Cancer. 2014;111:1381–1390. doi:10.1038/bjc.2014.420.
   PubMed Web of Science ®Google Scholar
• Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol. 2011;24:1470–1479. doi:10.1038/modpathol.2011.107.
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Mano R, Ciriello G, Gonen M, Mikkilineni N, Sfakianos JP, Kim PH, Motzer RJ, Russo P, Reuter VE, et al. Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma. J Urol. 2014;192:24–29. doi:10.1016/j.juro.2014.01.088.
   PubMed Web of Science ®Google Scholar
• Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D’Andrea K, Attiyeh EF, Simon MC, Nathanson KL. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res. 2012;72:112–121. doi:10.1158/0008-5472.CAN-11-1698.
   PubMed Web of Science ®Google Scholar
• Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 2017;24:1488–1501. doi:10.1038/cdd.2017.99.
   PubMed Web of Science ®Google Scholar
• Carlucci A, Gedressi C, Lignitto L, Nezi L, Villa-Moruzzi E, Avvedimento EV, Gottesman M, Garbi C, Feliciello A. Protein-tyrosine phosphatase PTPD1 regulates focal adhesion kinase autophosphorylation and cell migration. J Biol Chem. 2008;283:10919–10929. doi:10.1074/jbc.M707248200.
   PubMed Web of Science ®Google Scholar
• Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, Campbell S, Elson P, Koscielny S, Lopatin M, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 2015;16:676–685. doi:10.1016/S1470-2045(15)70167-1.
   PubMed Web of Science ®Google Scholar
• Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, et al. Predicting renal cancer recurrence: defining limitations of existing prognostic models with prospective trial-based validation. J Clin Oncol. 2019;37:2062–2071. doi:10.1200/JCO.19.00107.
   PubMed Web of Science ®Google Scholar
• Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105. doi:10.1016/j.eururo.2016.02.029.
   PubMed Web of Science ®Google Scholar
• Pei J, Feder MM, Al-Saleem T, Liu Z, Liu A, Hudes GR, Uzzo RG, Testa JR. Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes Cancer. 2010;9:610–619.
   Google Scholar
• Pei J, Jhanwar SC, Testa JR. Chromothripsis in a case of TP53-deficient chronic lymphocytic leukemia. Leuk Res Rep. 2012;1:4–6. doi:10.1016/j.lrr.2012.09.001.
   PubMedGoogle Scholar